Poly (D, L-lactide-co-glycolide)/DNA microspheres to facilitate prolonged transgene expression in airway epithelium in vitro, ex vivo and in vivo

PELGE Nanoparticles as New Carriers for the Delivery of Plasmid DNA

“…As it has been explained for PLGA nanoparticles, the first phase is attributed to the surface located molecules, while the second phase corresponds to the release following the degradation-erosion of the particles. 6) However, the block copolymer showed a double release mechanism: diffusion release duo to mPEG segments and degradation-erosion release duo to PLGA seg- ment. The aqueous pores or channels created by mPEG segments would accelerate the release of pDNA from nanoparticles during the rapid releasing phase.…”

Formulating Poly(Lactide-Co-Glycolide) Particles for Plasmid DNA Delivery

“…21,34,46 Particles with a size range of 3.1-3.5 mm are obtained, with a decrease in the negative surface charge. 21 This results in PLL complexed release of DNA and delayed second phase release.…”

“…27 Sustained pDNA delivery using PLGA particles has shown significant potential in transfecting human arterial smooth muscles 28,33 and airway epithelia. 34 When PLGA particles are compared to conventional transfection reagents such as FuGENE TM , initially lower transfection efficiency is obtained from the PLGA particles. An exponential decline in transfection level is noticed for the FuGENE TM transfection agent, whereas sustained levels are generated from the particles.…”

Gene therapy progress and prospects: cystic fibrosis

“…Although novel non-viral formulations are constantly being developed, [24][25][26][27][28] careful side-by-side comparison with existing 'gold standard' non-viral formulations in relevant in vivo models is generally missing. In an attempt to address this, the UK CF Gene Therapy Consortium (www.cfgenetherapy.org.uk) has set up a mouse core facility to compare existing non-viral formulations by actively recruiting formulations from academic and industrial partners.…”